Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 27Premenopausal Breast Cancer 2Breast Neoplasms, Male 2Sexual Dysfunctions, Psychological 1Patient Compliance 1Hereditary Sensory and Autonomic Neuropathies 1HER2-positive Breast Cancer 1Breast Cancer Invasive 1

Interventions

Fulvestrant 10Letrozole 4Alpelisib 4ribociclib 3palbociclib 3Paclitaxel 2NVP-BKM120 2volagidemab 1serabelisib 1sapanisertib 1olaparib 1liposomal doxorubicin 1gedatolisib 1exemestane 1dapagliflozin 1capivasertib 1abemaciclib 1Taxes 1Tamoxifen 1Secretin 1STX-478 1Metformin 1Lomustine 1Leuprolide 1Irinotecan 1Imlunestrant 1Goserelin 1Gemcitabine 1Drug Therapy 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × Leuprolide × Breast × Clear all
NCT03056755 2026-01-13

BYLieve

Novartis

Phase 2 Completed
383 enrolled 16 charts
Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡